Therapy of adult acute leukemia with daunorubicin and L‐asparaginase

Gerald P. Bodey; James S. Hewlett; Charles A. Coltman; Victorio Rodriguez; Emil J. Freireich

doi:10.1002/1097-0142(197403)33:3<626::AID-CNCR2820330306>3.0.CO;2-5

Therapy of adult acute leukemia with daunorubicin and L‐asparaginase

Gerald P. Bodey, James S. Hewlett, Charles A. Coltman, Victorio Rodriguez, Emil J. Freireich

Leukemia

Research output: Contribution to journal › Article › peer-review

23 Scopus citations

Abstract

Fifty‐four adults with acute leukemia resistant to other therapies received treatment with Daunorubicin and L‐asparaginase. Seventeen (31%) achieved complete remission. The complete remission rate was higher among the 31 patients receiving simultaneous therapy than among the 23 patients receiving sequential therapy (42% vs. 17%). Patients with acute lymphocytic leukemia had a higher remission rate than patients with acute myelogenous leukemia (38% vs. 20%). The median duration of complete remission was only 12 weeks, and the median duration of survival for responders was 30 weeks.

Original language	English (US)
Pages (from-to)	626-630
Number of pages	5
Journal	Cancer
Volume	33
Issue number	3
DOIs	https://doi.org/10.1002/1097-0142(197403)33:3<626::AID-CNCR2820330306>3.0.CO;2-5
State	Published - Mar 1974

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1002/1097-0142(197403)33:3<626::AID-CNCR2820330306>3.0.CO;2-5

Cite this

@article{d393cbea77524a828c68d2b21fe6396c,

title = "Therapy of adult acute leukemia with daunorubicin and L‐asparaginase",

abstract = "Fifty‐four adults with acute leukemia resistant to other therapies received treatment with Daunorubicin and L‐asparaginase. Seventeen (31%) achieved complete remission. The complete remission rate was higher among the 31 patients receiving simultaneous therapy than among the 23 patients receiving sequential therapy (42% vs. 17%). Patients with acute lymphocytic leukemia had a higher remission rate than patients with acute myelogenous leukemia (38% vs. 20%). The median duration of complete remission was only 12 weeks, and the median duration of survival for responders was 30 weeks.",

author = "Bodey, {Gerald P.} and Hewlett, {James S.} and Coltman, {Charles A.} and Victorio Rodriguez and Freireich, {Emil J.}",

year = "1974",

month = mar,

doi = "10.1002/1097-0142(197403)33:3<626::AID-CNCR2820330306>3.0.CO;2-5",

language = "English (US)",

volume = "33",

pages = "626--630",

journal = "Cancer",

issn = "0008-543X",

publisher = "John Wiley and Sons Inc.",

number = "3",

}

TY - JOUR

T1 - Therapy of adult acute leukemia with daunorubicin and L‐asparaginase

AU - Bodey, Gerald P.

AU - Hewlett, James S.

AU - Coltman, Charles A.

AU - Rodriguez, Victorio

AU - Freireich, Emil J.

PY - 1974/3

Y1 - 1974/3

N2 - Fifty‐four adults with acute leukemia resistant to other therapies received treatment with Daunorubicin and L‐asparaginase. Seventeen (31%) achieved complete remission. The complete remission rate was higher among the 31 patients receiving simultaneous therapy than among the 23 patients receiving sequential therapy (42% vs. 17%). Patients with acute lymphocytic leukemia had a higher remission rate than patients with acute myelogenous leukemia (38% vs. 20%). The median duration of complete remission was only 12 weeks, and the median duration of survival for responders was 30 weeks.

AB - Fifty‐four adults with acute leukemia resistant to other therapies received treatment with Daunorubicin and L‐asparaginase. Seventeen (31%) achieved complete remission. The complete remission rate was higher among the 31 patients receiving simultaneous therapy than among the 23 patients receiving sequential therapy (42% vs. 17%). Patients with acute lymphocytic leukemia had a higher remission rate than patients with acute myelogenous leukemia (38% vs. 20%). The median duration of complete remission was only 12 weeks, and the median duration of survival for responders was 30 weeks.

UR - http://www.scopus.com/inward/record.url?scp=0015984041&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0015984041&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(197403)33:3<626::AID-CNCR2820330306>3.0.CO;2-5

DO - 10.1002/1097-0142(197403)33:3<626::AID-CNCR2820330306>3.0.CO;2-5

M3 - Article

C2 - 4521886

AN - SCOPUS:0015984041

SN - 0008-543X

VL - 33

SP - 626

EP - 630

JO - Cancer

JF - Cancer

IS - 3

ER -

Therapy of adult acute leukemia with daunorubicin and L‐asparaginase

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this